Nurix Therapeutics Inc Quick Ratio (NRIX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nurix Therapeutics Inc   (NASDAQ: NRIX)

Nurix Therapeutics Inc 's Quick Ratio

NRIX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nurix Therapeutics Inc 's Cash & cash equivalent grew by 962 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Nurix Therapeutics Inc 's Quick Ratio to 5.51, above Nurix Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 175 other companies have achieved higher Quick Ratio than Nurix Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 759, from total ranking in the second quarter 2026 at 1852.

Explain Quick Ratio?
How much Cash & cash equivalents NRIX´s has?
What are NRIX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NRIX/financial-strength
https://api.csimarket.com/api/v1/companies/NRIX/fundamentals
https://api.csimarket.com/api/v1/companies/NRIX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NRIX Quick Ratio (Aug 31 2026)
Q3		 (May 31 2026)
Q2 		(Feb 28 2026)
Q1 		(Nov 30 2025)
Q4 		(Aug 31 2025)
Q3
Y / Y Current Liabilities Change 58.76 %
Y / Y Cash & cash equivalent Change 818.51 %
Quick Ratio MRQ 5.51
NRIX's Total Ranking # 759
Seq. Current Liabilities Change 81.54 %
Seq. Cash & cash equivalent Change 962 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 176
Healthcare Sector # 285
Overall Market # 759


Quick Ratio Statistics
High Average Low
8.64 3.58 0.57
(Aug 31 2020)   (Feb 29 2024)




Financial Statements
Nurix Therapeutics Inc 's Current Liabilities $ 131 Millions Visit NRIX's Balance sheet
Nurix Therapeutics Inc 's Cash & cash equivalent $ 720 Millions Visit NRIX's Balance sheet
Source of NRIX's Sales Visit NRIX's Sales by Geography


Cumulative Nurix Therapeutics Inc 's Quick Ratio

NRIX's Quick Ratio for the trailling 12 Months

NRIX Quick Ratio

 (Aug 31 2026)
12 Months		 (May 31 2026)
12 Months 		(Feb 28 2026)
12 Months 		(Nov 30 2025)
12 Months 		(Aug 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 10.94 %
Y / Y Cash & cash equivalent TTM Growth 217.39 %
Quick Ratio TTM 2.9
Total Ranking TTM # 994
Seq. Current Liabilities TTM Growth 14.53 %
Seq. Cash & cash equivalent TTM Growth 138.24 %

Quick ratio ranking by company, industry and sector >> Back to NRIX Financial Strength Comparisons >> Go to Compare NRIX Quick Ratio to its Competitors

On the trailing twelve months basis NRIX Cash & cash equivalent more than doubled by 818.51 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Nurix Therapeutics Inc 's Quick Ratio to 2.9, above NRIX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Nurix Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3735, from total ranking during the twelve months ending second quarter 2026 at 3893.

Explain Quick Ratio?
How much Cash & cash equivalents NRIX´s has?
What are NRIX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 429
Healthcare Sector # 873
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
3.88 1.53 0.66
(May 31 2021)   (Nov 30 2023)




Companies with similar Quick Ratio in the quarter ending Aug 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioAug 31 2026 MRQ Cash & cash equivalentAug 31 2026 MRQ Current Liabilities
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Structure Therapeutics Inc   11.62 $ 1,244.661  Millions$ 107.104  Millions
Immunome Inc   11.27 $ 461.582  Millions$ 40.966  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions
Xenon Pharmaceuticals Inc   10.99 $ 950.798  Millions$ 86.487  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Abcellera Biologics Inc   10.85 $ 764.424  Millions$ 70.473  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions
Bicycle Therapeutics Plc  10.57 $ 469.928  Millions$ 44.459  Millions
Lipocine Inc   10.55 $ 21.455  Millions$ 2.034  Millions
Cyclerion Therapeutics Inc   10.32 $ 456.221  Millions$ 44.197  Millions
Lexicon Pharmaceuticals Inc   10.31 $ 183.203  Millions$ 17.773  Millions
Adicet Bio Inc   10.28 $ 174.779  Millions$ 16.996  Millions
An2 Therapeutics Inc   10.26 $ 64.400  Millions$ 6.275  Millions
Pmv Pharmaceuticals Inc   10.15 $ 108.515  Millions$ 10.689  Millions
Nuvectis Pharma inc   9.91 $ 140.707  Millions$ 14.193  Millions
Renovorx Inc   9.76 $ 20.404  Millions$ 2.091  Millions

Date modified: 2026-10-14T16:57:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.